University of Utah researchers report that Ozempic, or Semaglutide — an injectable drug developed for diabetes and now popular for weight loss — may also alter muscle strength and size in mouse models.
Debuting in U.S. markets in December 2017, Semaglutide was originally developed to help people with type 2 diabetes control blood sugar by activating the body’s GLP-1 receptor, giving rise to the GLP-1 drug class. In 2021, it was approved as a weight-loss treatment under the brand name Wegovy. By 2024, an estimated 1 in 8 U.S. adults reported trying a GLP-1 drug.
Experimental design
Katsu Funai, the study’s principal investigator and an associate professor of nutrition and integrative physiology at the U, spent two years pursuing this hypothesis, building on his earlier research into diabetes-related organs.
Funai and his colleagues published the study on Aug. 6, 2025, hypothesizing that Semaglutide’s weight loss effects extend beyond fat to also impact lean mass, including muscle. Lean mass includes everything in the body that isn’t fat, such as muscle, bone, organs and water.
To run the experiment, the team placed male mice on a high-fat diet for 12 weeks to induce obesity. They then administered daily Semaglutide injections, with one group receiving doses proportional to human treatments and the other receiving higher-than-usual amounts.
The team tested the mice for body composition, hindlimb muscle mass and force-generating capacity before and after injections.
“The studies took nine months, which is obviously pretty quick,” Funai said. “That’s the advantage of using a mouse, [although] it’s not a perfect model by any means.”
He explained that mouse models allow direct dissection and precise measurement of muscle mass, while human testing methods like MRIs can only provide estimates.
Findings
The study revealed that Semaglutide reduced fat mass in mice by 43–52% and lean mass by 9–14%, mostly during the first week. Fast-twitch muscles — responsible for short, powerful bursts such as sprinting or weightlifting — showed a 20% decline in force capacity in the same period. However, slow-twitch muscles were not affected.
“It’s true that bigger muscles usually indicate more strength, but that’s not always the case,” Funai said.
He noted that when people are on bed rest, their muscles slowly start to shrink; however, muscle mass and strength decline at different rates. In the study, low-dose injections caused an initial force reduction that later went back to normal, while high-dose injections caused losses that persisted beyond the experiment.
The future of Ozempic
As the popularity of Ozempic increases, researchers will continue to examine its broader effects.
“Some worry these drugs may cause muscle loss, but the evidence is limited,” Funai said. “Companies are already developing combination treatments to preserve muscle. While the concern is valid, the greater health risks come from conditions like diabetes and obesity. We need more research to understand the effects fully.”
The American Medical Association (AMA) interviewed Dr. Ethan Lazarus, a physician who specializes in obesity and family medicine. Lazarus emphasized that obesity is a chronic illness, so patients should take medications like Semaglutide over the long term.
“If a person loses weight on an anti-obesity medication and stops it, most of the clinical studies have shown that they’ll regain at least two-thirds of the lost weight within 12 months,” Lazarus said. “And within a couple years they usually are back to where they started.”
Funai cautioned against drawing premature conclusions, reminding patients with diabetes and obesity not to worry about the drug’s potential muscle effects until further research is done.
“The benefits these medications provide for people with diabetes or obesity far outweigh the small amount of muscle mass that may be lost,” Funai said. “We need to remember [that] these are life-saving drugs.”
The post U Researchers Link Ozempic to Muscle Changes first appeared on The Daily Utah Chronicle.